RxDoctor Payments Data

David Podwall, MD

Neurology · Lake Success, NYNPI 1124072418

Payments from drug & device makers

$499,707in general payments, 2019–2025

Across 1,039 payments — averaging $480.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$334K
  • Eli Lilly$96K
  • Eisai Inc.$38K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$13K
  • Merck$3K
  • AbbVie$3K
  • plus $13K from 54 others
$17,758in research payments, 2019–2025

Across 1 payment — averaging $17,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$18K

What the payments were for

  • Consulting fees$5,30710%
  • Speaking & faculty fees$26,66749%
  • Travel & lodging$3,1386%
  • Food & beverage$18,76535%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS86$333,816
Eli Lilly7$96,109
Eisai Inc.86$37,737
Otsuka Pharmaceutical Development & Commercialization, Inc.1$13,100
Merck2$2,806
AbbVie(2 entities)139$2,606
Amgen(2 entities)65$1,263
Pfizer69$964
SK Life Science, Inc.47$836
Lundbeck LLC56$698
AstraZeneca(2 entities)25$588
Novartis41$518
EMD Serono, Inc.24$508
Biogen32$470
Grifols USA, LLC18$440
Biohaven Pharmaceuticals, Inc.13$426
Scilex Pharmaceuticals Inc.20$425
Acadia Pharmaceuticals Inc30$419
Takeda Pharmaceuticals U.S.A., Inc.15$419
UCB, Inc.13$345
Teva Pharmaceuticals USA, Inc.14$341
Biohaven Pharmaceutical Holding Company Ltd.20$334
Neurocrine Biosciences, Inc.14$326
Argenx US, Inc.14$315
Lilly USA, LLC16$314
Bristol Myers Squibb16$259
Sanofi13$236
MDD US Operations, LLC11$206
Otsuka America Pharmaceutical, Inc.9$199
Amylyx Pharmaceuticals, Inc.5$179
Sunovion Pharmaceuticals Inc.10$166
Kyowa Kirin, Inc.7$155
CSL Behring7$147
Medtronic4$144
Impel Pharmaceuticals Inc.5$144
Amneal Pharmaceuticals LLC7$141
Tanabe Pharma America, Inc.6$133
Genentech USA, Inc.3$86
Vertex3$85
GE HealthCare4$84
Octapharma USA, Inc.4$77
TG Therapeutics, Inc.2$74
Upsher-smith Laboratories LLC4$71
Neuronetics, Inc.2$69
Catalyst Pharmaceuticals, Inc.4$66
Corium, LLC4$64
Acorda Therapeutics, Inc4$62
Boehringer Ingelheim2$56
Vertical Pharmaceuticals, LLC3$51
Supernus Pharmaceuticals, Inc.3$49
Mallinckrodt Hospital Products Inc.3$49
Ipsen Biopharmaceuticals, Inc2$48
Neurelis, Inc.1$42
Banner Life Sciences, LLC2$39
Almatica Pharma LLC2$37
Johnson & Johnson1$33
Axsome Therapeutics, Inc.1$32
Vanda Pharmaceuticals Inc.2$32
Boston Scientific1$28
Bausch Health US, LLC2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$499,707 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$358,545
Medicare patients
998
Services billed
3,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl ErMemantine Hcl365$41,847
XcopriCenobamate20$26,909
Rivastigmine78$20,449
Memantine Hcl133$8,201
Donepezil Hcl394$4,982
Carbamazepine ErCarbamazepine19$3,904
Gabapentin214$3,154
Pregabalin80$2,843
Quetiapine Fumarate100$1,939
Nortriptyline Hcl105$1,561
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$1,490
Carbidopa-LevodopaCarbidopa/Levodopa65$1,453
Levetiracetam45$1,421
Sertraline Hcl76$1,271
Escitalopram Oxalate86$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$836$26,90920 claims
Almatica Pharma LLCSertraline Hcl$37$1,27176 claims
Upsher-smith Laboratories LLCTopiramate$71$77378 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Lake Success

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →